がん免疫療法薬の市場：タイプ、適応症、エンドユーザー別-2025-2030年の世界予測

がん免疫療法薬市場は、2023年に2,152億9,000万米ドルと評価され、2024年には2,433億1,000万米ドルに達すると予測され、CAGR 13.10％で成長し、2030年には5,099億3,000万米ドルに達すると予測されています。

がん免疫療法薬は、がんと闘うために患者の免疫系を活用することに焦点を当てた、急速に進化するがん治療分野の代表です。この革新的なアプローチには、チェックポイント阻害剤、がんワクチン、CAR-T細胞療法など様々な治療法が含まれ、がん細胞を認識し破壊する免疫系の自然な能力を向上させるように設計されています。これらの薬剤の必要性は、従来の化学療法に比べて副作用が少なく、より個別化された効果的ながん治療を提供できる可能性に由来します。その応用範囲は、メラノーマ、肺がん、リンパ腫など幅広いがんに及び、これらの分野におけるアンメット・メディカル・ニーズに対応しています。最終用途の範囲には、病院、がん研究機関、専門クリニックが含まれ、これらの治療法の投与とモニタリングに極めて重要です。

市場成長の主な要因は、がん罹患率の増加、バイオテクノロジーの進歩、精密医療に対する需要の高まりです。また、FDA承認の加速や研究開発への多額の投資も寄与しています。ヘルスケアのインフラが整備されつつある新興市場にはビジネスチャンスが存在し、先進治療へのアクセス拡大が可能になります。さらに、バイオテクノロジー企業と学術機関との協力関係も、この分野での技術革新を推進する可能性があります。しかし、治療費の高騰、複雑な製造工程、厳格な規制枠組といった限界に直面し、普及への課題となっています。また、特許切れやバイオシミラーの出現も大きなハードルとなっています。

事業の成長とイノベーションを促進するためには、異なる免疫療法アプローチを利用した併用療法の調査に注力することが有望な結果をもたらす可能性があります。さらに、より良い患者選択のためのバイオマーカーの探索や、費用対効果の高い製造技術の開発は、既存の課題を軽減する可能性があります。企業は、急速に変化する規制環境に適応するための機敏性を維持し、研究開発能力を高めるパートナーシップを追求すべきです。これらの分野に取り組むことで、利害関係者は新たな成長の道を切り開き、この変革的な市場での地位を確固たるものにするとともに、がん治療の進歩に貢献することができます。

市場力学：急速に進化するがん免疫療法薬市場における主要な市場洞察の解明

がん免疫療法薬市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的決定の精緻化、そして新たなビジネスチャンスの獲得に備えることができます。これらの動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができ、また、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • 世界のがん有病率の上昇
  • 他の治療法に対する免疫療法の採用拡大
  • がん免疫療法研究のためのバイオインフォマティクスツールとリソースの開発
• 市場抑制要因
  • 治療費の高騰と免疫腫瘍薬の効果の不確実性
• 市場機会
  • 最近の免疫療法技術の動向
  • 免疫療法研究への多額の投資と資金提供
• 市場の課題
  • 利用可能な治療法の副作用の可能性

ポーターの5つの力：がん免疫療法薬市場をナビゲートする戦略ツール

ポーターの5つの力フレームワークは、市場情勢の競合情勢を理解するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することで、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：がん免疫療法薬市場における外部からの影響の把握

外部マクロ環境要因は、がん免疫療法薬市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析がん免疫療法薬市場における競合情勢の把握

がん免疫療法薬市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニング・マトリックスがん免疫療法薬市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、がん免疫療法薬市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によってベンダーを明確かつ正確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨がん免疫療法薬市場における成功への道筋を描く

がん免疫療法薬市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を見直すことで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネスチャンスを活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目分野を網羅した市場の包括的な分析を提供しています：

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力の評価。

2.市場の開拓度：新興市場における成長機会を特定し、既存分野における拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化：最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています：

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、セグメント、地域はどこか？

3.市場を形成する主な技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 世界中でがんの罹患率が上昇
    • 他の治療法よりも免疫療法の採用が増加
    • がん免疫療法研究のためのバイオインフォマティクスツールとリソースの開発
  • 抑制要因
    • 治療費の高さと免疫腫瘍薬の予測不可能な有効性
  • 機会
    • 免疫療法技術の最近の動向
    • 免疫療法調査への多額の投資と資金提供
  • 課題
    • 利用可能な治療法の副作用の可能性
• 市場セグメンテーション分析
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社交
  • 技術的
  • 法律上
  • 環境

第6章 がん免疫療法薬の市場：タイプ別

• がんワクチン
• チェックポイント阻害剤
• 免疫調節薬
• モノクローナル抗体

第7章 がん免疫療法薬の市場適応症別

• 乳がん
• 大腸がん
• 頭頸部がん
• 肺がん
• 悪性黒色腫
• 前立腺がん

第8章 がん免疫療法薬の市場：エンドユーザー別

• 外来手術センター
• 病院・クリニック

第9章 南北アメリカのがん免疫療法薬の市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第10章 アジア太平洋地域のがん免疫療法薬の市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第11章 欧州・中東・アフリカのがん免疫療法薬の市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第12章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス, 2023
• 競合シナリオ分析
• 戦略分析と提言

企業一覧

• AbbVie, Inc.
• Amgen Inc.
• Astellas Pharma Inc.
• AstraZeneca PLC
• Bayer AG
• Boehringer Ingelheim International GmbH
• Bristol Myers Squibb Company
• CARsgen Therapeutics
• Celldex Therapeutics, Inc.
• ElevateBio
• ELI Lilly and Company
• F. Hoffmann-La Roche Ltd
• Gilead Sciences, Inc.
• GlaxoSmithKline PLC
• Ikena Oncology
• Incyte Corporation
• Johnson & Johnson Services, Inc.
• Merck & Co., Inc.
• Novartis AG
• OSE Immunotherapeutics SA
• Pfizer Inc.
• QIAGEN N.V.
• Sanofi SA
• Seattle Genetics Inc.
• Takeda Pharmaceutical Company Limited

LIST OF FIGURES

• FIGURE 1. CANCER IMMUNOTHERAPY DRUGS MARKET RESEARCH PROCESS
• FIGURE 2. CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. AMERICAS CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 13. AMERICAS CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. UNITED STATES CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 15. UNITED STATES CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. ASIA-PACIFIC CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 17. ASIA-PACIFIC CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. EUROPE, MIDDLE EAST & AFRICA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 19. EUROPE, MIDDLE EAST & AFRICA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. CANCER IMMUNOTHERAPY DRUGS MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 21. CANCER IMMUNOTHERAPY DRUGS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. CANCER IMMUNOTHERAPY DRUGS MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. CANCER IMMUNOTHERAPY DRUGS MARKET DYNAMICS
• TABLE 7. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY CANCER VACCINES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY IMMUNOMODULATORS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY HEAD & NECK CANCER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY MELANOMA, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY AMBULATORY SURGICAL CENTER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 21. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 22. AMERICAS CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 23. AMERICAS CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 24. AMERICAS CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 25. AMERICAS CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 26. ARGENTINA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 27. ARGENTINA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 28. ARGENTINA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 29. BRAZIL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 30. BRAZIL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 31. BRAZIL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 32. CANADA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 33. CANADA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 34. CANADA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 35. MEXICO CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 36. MEXICO CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 37. MEXICO CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 38. UNITED STATES CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 39. UNITED STATES CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 40. UNITED STATES CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 41. UNITED STATES CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 42. ASIA-PACIFIC CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 43. ASIA-PACIFIC CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 44. ASIA-PACIFIC CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 45. ASIA-PACIFIC CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 46. AUSTRALIA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 47. AUSTRALIA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 48. AUSTRALIA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 49. CHINA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 50. CHINA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 51. CHINA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 52. INDIA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 53. INDIA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 54. INDIA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 55. INDONESIA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 56. INDONESIA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 57. INDONESIA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 58. JAPAN CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 59. JAPAN CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 60. JAPAN CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 61. MALAYSIA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 62. MALAYSIA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 63. MALAYSIA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 64. PHILIPPINES CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 65. PHILIPPINES CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 66. PHILIPPINES CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 67. SINGAPORE CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 68. SINGAPORE CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 69. SINGAPORE CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 70. SOUTH KOREA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 71. SOUTH KOREA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 72. SOUTH KOREA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 73. TAIWAN CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 74. TAIWAN CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 75. TAIWAN CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 76. THAILAND CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 77. THAILAND CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 78. THAILAND CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 79. VIETNAM CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 80. VIETNAM CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 81. VIETNAM CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 82. EUROPE, MIDDLE EAST & AFRICA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 83. EUROPE, MIDDLE EAST & AFRICA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 84. EUROPE, MIDDLE EAST & AFRICA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 85. EUROPE, MIDDLE EAST & AFRICA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 86. DENMARK CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 87. DENMARK CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 88. DENMARK CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 89. EGYPT CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 90. EGYPT CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 91. EGYPT CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 92. FINLAND CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 93. FINLAND CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 94. FINLAND CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 95. FRANCE CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 96. FRANCE CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 97. FRANCE CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 98. GERMANY CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 99. GERMANY CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 100. GERMANY CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 101. ISRAEL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 102. ISRAEL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 103. ISRAEL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 104. ITALY CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 105. ITALY CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 106. ITALY CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 107. NETHERLANDS CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 108. NETHERLANDS CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 109. NETHERLANDS CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 110. NIGERIA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 111. NIGERIA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 112. NIGERIA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 113. NORWAY CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 114. NORWAY CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 115. NORWAY CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 116. POLAND CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 117. POLAND CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 118. POLAND CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 119. QATAR CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 120. QATAR CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 121. QATAR CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 122. RUSSIA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 123. RUSSIA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 124. RUSSIA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 125. SAUDI ARABIA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 126. SAUDI ARABIA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 127. SAUDI ARABIA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 128. SOUTH AFRICA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 129. SOUTH AFRICA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 130. SOUTH AFRICA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 131. SPAIN CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 132. SPAIN CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 133. SPAIN CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 134. SWEDEN CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 135. SWEDEN CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 136. SWEDEN CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 137. SWITZERLAND CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 138. SWITZERLAND CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 139. SWITZERLAND CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 140. TURKEY CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 141. TURKEY CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 142. TURKEY CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 143. UNITED ARAB EMIRATES CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 144. UNITED ARAB EMIRATES CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 145. UNITED ARAB EMIRATES CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 146. UNITED KINGDOM CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 147. UNITED KINGDOM CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 148. UNITED KINGDOM CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 149. CANCER IMMUNOTHERAPY DRUGS MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 150. CANCER IMMUNOTHERAPY DRUGS MARKET, FPNV POSITIONING MATRIX, 2023

The Cancer Immunotherapy Drugs Market was valued at USD 215.29 billion in 2023, expected to reach USD 243.31 billion in 2024, and is projected to grow at a CAGR of 13.10%, to USD 509.93 billion by 2030.

Cancer immunotherapy drugs represent a rapidly evolving segment of oncology treatment, focusing on harnessing the patient's immune system to combat cancer. This innovative approach encompasses various therapies, including checkpoint inhibitors, cancer vaccines, and CAR-T cell therapies, which are designed to improve the immune system's natural ability to recognize and destroy cancer cells. The necessity of these drugs stems from their potential to offer more personalized and effective cancer treatments with fewer side effects compared to traditional chemotherapy. Their application covers a broad spectrum of cancers, such as melanoma, lung cancer, and lymphomas, addressing the unmet medical needs in these areas. The end-use scope includes hospitals, cancer research institutes, and specialized clinics, which are pivotal for the administration and monitoring of these therapies.

Market growth is primarily driven by increased cancer prevalence, advancements in biotechnology, and a rising demand for precision medicine. The accelerated FDA approvals and substantial investments in R&D are also contributing factors. Opportunities exist in emerging markets where healthcare infrastructure is improving, enabling greater access to advanced therapies. Additionally, collaborations between biotechnology companies and academic institutions could propel innovation within this field. However, the market faces limitations such as high treatment costs, complex manufacturing processes, and stringent regulatory frameworks, which pose challenges to widespread adoption. Navigating patent expirations and the emergence of biosimilars also present significant hurdles.

To foster business growth and innovation, a focus on researching combination therapies that utilize different immunotherapy approaches could yield promising results. Additionally, exploring biomarkers for better patient selection and developing cost-effective manufacturing technologies could mitigate some of the existing challenges. Companies should maintain agility to adapt to rapidly changing regulatory environments and pursue partnerships that enhance their R&D capabilities. By addressing these areas, stakeholders can unlock new growth avenues and solidify their position in this transformative market while contributing to progressive cancer treatment advancements.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Cancer Immunotherapy Drugs Market

The Cancer Immunotherapy Drugs Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Rise in prevalence of cancer across the world
  • Growing adoption of immunotherapy over other treatments
  • Developments of bioinformatics tools and resources for cancer immunotherapy study
• Market Restraints
  • High cost of therapy and unpredictable effectiveness of immuno-oncology agents
• Market Opportunities
  • Recent developments in immunotherapy technologies
  • Significant investment and funding for immunotherapy research
• Market Challenges
  • Possibilities of adverse effects of the available therapies

Porter's Five Forces: A Strategic Tool for Navigating the Cancer Immunotherapy Drugs Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Cancer Immunotherapy Drugs Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Cancer Immunotherapy Drugs Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Cancer Immunotherapy Drugs Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Cancer Immunotherapy Drugs Market

A detailed market share analysis in the Cancer Immunotherapy Drugs Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Cancer Immunotherapy Drugs Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Cancer Immunotherapy Drugs Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Cancer Immunotherapy Drugs Market

A strategic analysis of the Cancer Immunotherapy Drugs Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Cancer Immunotherapy Drugs Market, highlighting leading vendors and their innovative profiles. These include AbbVie, Inc., Amgen Inc., Astellas Pharma Inc., AstraZeneca PLC, Bayer AG, Boehringer Ingelheim International GmbH, Bristol Myers Squibb Company, CARsgen Therapeutics, Celldex Therapeutics, Inc., ElevateBio, ELI Lilly and Company, F. Hoffmann-La Roche Ltd, Gilead Sciences, Inc., GlaxoSmithKline PLC, Ikena Oncology, Incyte Corporation, Johnson & Johnson Services, Inc., Merck & Co., Inc., Novartis AG, OSE Immunotherapeutics SA, Pfizer Inc., QIAGEN N.V., Sanofi SA, Seattle Genetics Inc., and Takeda Pharmaceutical Company Limited.

Market Segmentation & Coverage

This research report categorizes the Cancer Immunotherapy Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Type, market is studied across Cancer Vaccines, Checkpoint Inhibitors, Immunomodulators, and Monoclonal Antibodies.
• Based on Indication, market is studied across Breast Cancer, Colorectal Cancer, Head & Neck Cancer, Lung Cancer, Melanoma, and Prostate Cancer.
• Based on End-user, market is studied across Ambulatory Surgical Center and Hospitals & Clinics.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Rise in prevalence of cancer across the world
    • 5.1.1.2. Growing adoption of immunotherapy over other treatments
    • 5.1.1.3. Developments of bioinformatics tools and resources for cancer immunotherapy study
  • 5.1.2. Restraints
    • 5.1.2.1. High cost of therapy and unpredictable effectiveness of immuno-oncology agents
  • 5.1.3. Opportunities
    • 5.1.3.1. Recent developments in immunotherapy technologies
    • 5.1.3.2. Significant investment and funding for immunotherapy research
  • 5.1.4. Challenges
    • 5.1.4.1. Possibilities of adverse effects of the available therapies
• 5.2. Market Segmentation Analysis
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Cancer Immunotherapy Drugs Market, by Type

• 6.1. Introduction
• 6.2. Cancer Vaccines
• 6.3. Checkpoint Inhibitors
• 6.4. Immunomodulators
• 6.5. Monoclonal Antibodies

7. Cancer Immunotherapy Drugs Market, by Indication

• 7.1. Introduction
• 7.2. Breast Cancer
• 7.3. Colorectal Cancer
• 7.4. Head & Neck Cancer
• 7.5. Lung Cancer
• 7.6. Melanoma
• 7.7. Prostate Cancer

8. Cancer Immunotherapy Drugs Market, by End-user

• 8.1. Introduction
• 8.2. Ambulatory Surgical Center
• 8.3. Hospitals & Clinics

9. Americas Cancer Immunotherapy Drugs Market

• 9.1. Introduction
• 9.2. Argentina
• 9.3. Brazil
• 9.4. Canada
• 9.5. Mexico
• 9.6. United States

10. Asia-Pacific Cancer Immunotherapy Drugs Market

• 10.1. Introduction
• 10.2. Australia
• 10.3. China
• 10.4. India
• 10.5. Indonesia
• 10.6. Japan
• 10.7. Malaysia
• 10.8. Philippines
• 10.9. Singapore
• 10.10. South Korea
• 10.11. Taiwan
• 10.12. Thailand
• 10.13. Vietnam

11. Europe, Middle East & Africa Cancer Immunotherapy Drugs Market

• 11.1. Introduction
• 11.2. Denmark
• 11.3. Egypt
• 11.4. Finland
• 11.5. France
• 11.6. Germany
• 11.7. Israel
• 11.8. Italy
• 11.9. Netherlands
• 11.10. Nigeria
• 11.11. Norway
• 11.12. Poland
• 11.13. Qatar
• 11.14. Russia
• 11.15. Saudi Arabia
• 11.16. South Africa
• 11.17. Spain
• 11.18. Sweden
• 11.19. Switzerland
• 11.20. Turkey
• 11.21. United Arab Emirates
• 11.22. United Kingdom

12. Competitive Landscape

• 12.1. Market Share Analysis, 2023
• 12.2. FPNV Positioning Matrix, 2023
• 12.3. Competitive Scenario Analysis
• 12.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. AbbVie, Inc.
• 2. Amgen Inc.
• 3. Astellas Pharma Inc.
• 4. AstraZeneca PLC
• 5. Bayer AG
• 6. Boehringer Ingelheim International GmbH
• 7. Bristol Myers Squibb Company
• 8. CARsgen Therapeutics
• 9. Celldex Therapeutics, Inc.
• 10. ElevateBio
• 11. ELI Lilly and Company
• 12. F. Hoffmann-La Roche Ltd
• 13. Gilead Sciences, Inc.
• 14. GlaxoSmithKline PLC
• 15. Ikena Oncology
• 16. Incyte Corporation
• 17. Johnson & Johnson Services, Inc.
• 18. Merck & Co., Inc.
• 19. Novartis AG
• 20. OSE Immunotherapeutics SA
• 21. Pfizer Inc.
• 22. QIAGEN N.V.
• 23. Sanofi SA
• 24. Seattle Genetics Inc.
• 25. Takeda Pharmaceutical Company Limited